April 14 (Reuters) - Swiss generic drug manufacturer Sandoz SDZ.S said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen AMGN.O for entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept).
(Reporting by Abinaya Vijayaraghavan; Editing by Rashmi Aich)
((Abinaya.V@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.